Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorZiver-Sarp, Tevhide
dc.contributor.authorYüksel-Mayda, Pelin
dc.contributor.authorSarıbaş, Suat
dc.contributor.authorDemiryaş, Süleyman
dc.contributor.authorGareayaghi, Nesrin
dc.contributor.authorErgin, Sevgi
dc.contributor.authorKocazeybek, Bekir
dc.contributor.authorDemirci, Mehmet
dc.date.accessioned2021-12-12T17:01:58Z
dc.date.available2021-12-12T17:01:58Z
dc.date.issued2021
dc.identifier.issn1433-6510
dc.identifier.urihttps://doi.org/10.7754/Clin.Lab.2021.210843
dc.identifier.urihttps://hdl.handle.net/20.500.11857/3345
dc.description.abstractBackground: Spontaneous point mutations in genes encoding gyrA/B subunits of DNA gyrase are responsible for fluoroquinolone resistance. We aimed to determine the clarithromycin and levofloxacin resistance phenotypically in H. pylori strains and to investigate the mutations responsible for levofloxacin resistance and the effects of these mutations on dual antibiotic resistance. Methods: A total of 65 H. pylori isolates were included. The E-test method was used for the clarithromycin and le-vofloxacin antimicrobial susceptibility test. Real-time PCR was used to detect the point mutations. Results: Twenty-four (36.9%) of 65 H. pylori strains were phenotypically resistant to clarithromycin and 14 (21.5%) to levofloxacin. The phenotypic levofloxacin resistance rate of strains with Asn87Lys and Asp91Asn mu-tations were significantly higher (gyrA gene) (p < 0.05). The phenotypic levofloxacin resistance rate of strains with Arg484Lys and Asp481Glu mutations were significantly higher (gyrB gene) (p < 0.05). The Asn87Lys mutation in-creased the risk of phenotypes being resistant to levofloxacin 70.156 times and Asp91Asn mutation increased 125,427 times higher. Seven (10.8%) of 65 H. pylori strains showed dual resistance to both levofloxacin and cla-rithromycin. The rate of being dual resistant with A2143G mutation (clarithromycin resistance) was found to be significantly higher (p < 0.05). Conclusions: The Asn87Lys and Asp91Asn mutations in the gyrA gene had a phenotypically enhancing effect on levofloxacin resistance, while the presence of Asp481Glu and Arg484Lys mutations in the gyrB gene did not. The existence of dual resistance was developed with the increase in clarithromycin and levofloxacin resistance rates. (Clin. Lab. 2021;67:2369-2377. DOI: 10.7754/Clin.Lab.2021.210843)en_US
dc.description.sponsorshipIstanbul University-Cerrahpasa Research Fund [45704]en_US
dc.description.sponsorshipThis work was supported by the Istanbul University-Cerrahpasa Research Fund under project number 45704.en_US
dc.language.isoengen_US
dc.publisherClin Lab Publen_US
dc.relation.ispartofClinical Laboratoryen_US
dc.identifier.doi10.7754/Clin.Lab.2021.210843
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectpoint mutationsen_US
dc.subjectHen_US
dc.subjectpylorien_US
dc.subjectgyrAen_US
dc.subjectgyrB geneen_US
dc.subjectlevofloxa-cin resistanceen_US
dc.subjectdual resistanceen_US
dc.titlePoint Mutations at gyrA and gyrB Genes of Levofloxacin Resistant Helicobacter pylori Strains and Dual Resistance with Clarithromycinen_US
dc.typearticle
dc.authoridDemirci, Mehmet/0000-0001-9670-2426
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri, Tıbbi Mikrobiyoloji Ana Bilim Dalı
dc.identifier.volume67en_US
dc.identifier.startpage2369en_US
dc.identifier.issue10en_US
dc.identifier.endpage2377en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid57298703900
dc.authorscopusid57297278300
dc.authorscopusid6603311139
dc.authorscopusid17134573300
dc.authorscopusid57208328718
dc.authorscopusid7003436003
dc.authorscopusid6603648543
dc.identifier.wosWOS:000707662400027en_US
dc.identifier.scopus2-s2.0-85117194653en_US
dc.identifier.pmidPubMed: 34655183en_US
dc.authorwosidDemirci, Mehmet/O-1886-2015


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster